Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Large B-cell Lymphoma: early-phase trial registry
20 of 29 indexed Large B-cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 20 currently recruiting · #552 of 28,707 conditions by registered trial count
Large B-cell Lymphoma: 29 US clinical trials tracked, 20 recruiting.
Large B-cell Lymphoma is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Lyell Immunopharma, running 2 of these trials.
Enrollment posture brief
Registry condition large-b-cell-lymphoma
OPEN 20 | RECR 69% | LATE 3 | EARLY 24 | RANK #552 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Deep Brain Stimulation (69% recruiting · 16 trials)
Large B-cell Lymphoma lists 20 open slots (69% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Large B-cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Large B-cell Lymphoma is recruiting above its size-band peers.
20 of 29 indexed trials (69%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Large B-cell Lymphoma trials is spread across many organizations.
Lyell Immunopharma accounts for 2 of 29 trials (6.9%). 22 distinct sponsors appear on at least one study for this condition label.
-
Most Large B-cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 36 among the 29 trials that report a genuine target (sentinel values excluded). 18 of those (62.1%) plan for fewer than 100 participants.
-
Large B-cell Lymphoma research is mostly interventional.
29 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma
NCT07188558
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
AstraZeneca
NCT06564038
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma
NCT05826535
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Allogene Therapeutics
NCT06500273
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
NCT06340737
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
NCT05643742
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Memorial Sloan Kettering Cancer Center
NCT05940272
CAR-T Followed by Bispecific Antibodies
Abramson Cancer Center at Penn Medicine
NCT04889716
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
M.D. Anderson Cancer Center
NCT06045247
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics
NCT06533579
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
M.D. Anderson Cancer Center
NCT05464719
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
H. Lee Moffitt Cancer Center and Research Institute
NCT06760156
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Marcela V. Maus, M.D.,Ph.D.
NCT06550141
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute
NCT06104592
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
University of Miami
NCT06919939
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Washington University School of Medicine
NCT07052305
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Estrella Biopharma
NCT06343311
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Joshua Sasine, MD, PhD
NCT05887167
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Stanford University
NCT05794958
BHB & CAR-T for Lymphomas
Abramson Cancer Center at Penn Medicine
NCT06610344
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Hoffmann-La Roche
NCT06047080
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Celgene
NCT06356129
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis Pharmaceuticals
NCT03960840
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT03642626
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta
NCT05020678
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Synthekine
NCT05665062
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05757700
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
Washington University School of Medicine
NCT05464329
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Sana Biotechnology
NCT06285422
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 9 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Large B-cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Large B-cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Large B-cell Lymphoma page
29 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Large B-cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Lyell Immunopharma sponsors the most Large B-cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Lyell Immunopharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Large B-cell Lymphoma condition card totals 29 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.